PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Evolving standards of care for resected pancreatic cancer.

Abstract Pancreatic cancer is a devastating illness, and surgical resection offers the only chance of a cure for patients with the disease. Relatively few patients have resectable disease at diagnosis, however, and the cancer frequently recurs even after complete surgical resection. This review discusses clinical trials in which adjuvant therapy with chemotherapy or chemoradiation has prolonged survival in patients following surgery. It also highlights new data from the ESPAC-4 and JASPAC 01 studies that may change the current treatment paradigm for adjuvant therapy. The ESPAC-4 results support the use of adjuvant gemcitabine plus capecitabine in preference to the previous standard of gemcitabine alone, demonstrating that in this instance, more may be better. Finally, the review discusses ongoing trials and new approaches that aim to improve outcomes further for patients with resectable pancreatic cancer.
PMID
Related Publications

Adjuvant treatments for resectable pancreatic cancer.

Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.

Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results.

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.

Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title clinical advances in hematology & oncology : h&o
Publication Year Start




PMID- 28398285
OWN - NLM
STAT- MEDLINE
DA  - 20170411
DCOM- 20170417
LR  - 20170417
IS  - 1543-0790 (Print)
IS  - 1543-0790 (Linking)
VI  - 15
IP  - 2
DP  - 2017 Feb
TI  - Evolving standards of care for resected pancreatic cancer.
PG  - 141-150
AB  - Pancreatic cancer is a devastating illness, and surgical resection offers the
      only chance of a cure for patients with the disease. Relatively few patients have
      resectable disease at diagnosis, however, and the cancer frequently recurs even
      after complete surgical resection. This review discusses clinical trials in which
      adjuvant therapy with chemotherapy or chemoradiation has prolonged survival in
      patients following surgery. It also highlights new data from the ESPAC-4 and
      JASPAC 01 studies that may change the current treatment paradigm for adjuvant
      therapy. The ESPAC-4 results support the use of adjuvant gemcitabine plus
      capecitabine in preference to the previous standard of gemcitabine alone,
      demonstrating that in this instance, more may be better. Finally, the review
      discusses ongoing trials and new approaches that aim to improve outcomes further 
      for patients with resectable pancreatic cancer.
FAU - Weinberg, Benjamin A
AU  - Weinberg BA
AD  - The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi
      Comprehensive Cancer Center, Washington, DC.
FAU - Philip, Philip A
AU  - Philip PA
AD  - Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
FAU - Salem, Mohamed E
AU  - Salem ME
AD  - The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi
      Comprehensive Cancer Center, Washington, DC.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Adv Hematol Oncol
JT  - Clinical advances in hematology & oncology : H&O
JID - 101167661
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Chemoradiotherapy, Adjuvant/methods
MH  - Humans
MH  - Pancreatectomy
MH  - Pancreatic Neoplasms/*therapy
MH  - Standard of Care/*trends
EDAT- 2017/04/12 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/12 06:00
PST - ppublish
SO  - Clin Adv Hematol Oncol. 2017 Feb;15(2):141-150.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>